Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
Cancer that develops in the ovaries (the egg-producing reproductive organs) is referred to as ovarian cancer. There are three types of ovarian cancer. Each type has differences in how they will ...
The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR ...
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting Ovarian carcinogenesis, as in ...
Nomograms have a strong reputation as reliable predictive models that simplify statistical prediction models and guide personalized treatment to formulate preventive measures for various diseases.
High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...
RICHMOND, Va. (WRIC) — September is Ovarian Cancer Awareness Month, bringing a critical health conversation to the forefront. As the deadliest of all female reproductive system cancers, ovarian cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback